Literature DB >> 16014719

Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.

Pascal Derkinderen1, Timothy M E Scales, Diane P Hanger, Kit-Yi Leung, Helen L Byers, Malcolm A Ward, Christof Lenz, Caroline Price, Ian N Bird, Timothy Perera, Stuart Kellie, Ritchie Williamson, Wendy Noble, Richard A Van Etten, Karelle Leroy, Jean-Pierre Brion, C Hugh Reynolds, Brian H Anderton.   

Abstract

Tau is a major microtubule-associated protein of axons and is also the principal component of the paired helical filaments (PHFs) that comprise the neurofibrillary tangles found in Alzheimer's disease and other tauopathies. Besides phosphorylation of tau on serine and threonine residues in both normal tau and tau from neurofibrillary tangles, Tyr-18 was reported to be a site of phosphorylation by the Src-family kinase Fyn. We examined whether tyrosine residues other than Tyr-18 are phosphorylated in tau and whether other tyrosine kinases might phosphorylate tau. Using mass spectrometry, we positively identified phosphorylated Tyr-394 in PHF-tau from an Alzheimer brain and in human fetal brain tau. When wild-type human tau was transfected into fibroblasts or neuroblastoma cells, treatment with pervanadate caused tau to become phosphorylated on tyrosine by endogenous kinases. By replacing each of the five tyrosines in tau with phenylalanine, we identified Tyr-394 as the major site of tyrosine phosphorylation in tau. Tyrosine phosphorylation of tau was inhibited by PP2 (4-amino-5-(4-chlorophenyl-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), which is known to inhibit Src-family kinases and c-Abl. Cotransfection of tau and kinases showed that Tyr-18 was the major site for Fyn phosphorylation, but Tyr-394 was the main residue for Abl. In vitro, Abl phosphorylated tau directly. Abl could be coprecipitated with tau and was present in pretangle neurons in brain sections from Alzheimer cases. These results show that phosphorylation of tau on Tyr-394 is a physiological event that is potentially part of a signal relay and suggest that Abl could have a pathogenic role in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014719      PMCID: PMC6725430          DOI: 10.1523/JNEUROSCI.1487-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  71 in total

1.  Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg.

Authors:  Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Tau is endogenously nitrated in mouse brain: identification of a tyrosine residue modified in vivo by NO.

Authors:  Simona Nonnis; Graziella Cappelletti; Francesca Taverna; Cristina Ronchi; Severino Ronchi; Armando Negri; Eleonora Grassi; Gabriella Tedeschi
Journal:  Neurochem Res       Date:  2007-09-02       Impact factor: 3.996

3.  Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases.

Authors:  Xin Wei; Lingjun Li
Journal:  Int J Clin Exp Pathol       Date:  2008-06-20

4.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

5.  Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain.

Authors:  Sarah D Schlatterer; Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  c-Abl in neurodegenerative disease.

Authors:  Sarah D Schlatterer; Christopher M Acker; Peter Davies
Journal:  J Mol Neurosci       Date:  2011-07-05       Impact factor: 3.444

7.  Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.

Authors:  Shannon N Campbell; Cheng Zhang; Louise Monte; Allyson D Roe; Kenner C Rice; Yvette Taché; Eliezer Masliah; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Selective tau tyrosine nitration in non-AD tauopathies.

Authors:  Juan F Reyes; Changiz Geula; Laurel Vana; Lester I Binder
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

9.  A possible link between astrocyte activation and tau nitration in Alzheimer's disease.

Authors:  Juan F Reyes; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Angela L Guillozet-Bongaarts; Robert Berry; Lester I Binder
Journal:  Neurobiol Dis       Date:  2008-05-02       Impact factor: 5.996

Review 10.  Novel therapeutic strategies for neurodegenerative disease.

Authors:  Hitoshi Tanimukai; Takashi Kudo; Toshihisa Tanaka; Inge Grundke-Iqbal; Khalid Iqbal; Masatoshi Takeda
Journal:  Psychogeriatrics       Date:  2009-06       Impact factor: 2.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.